Abstract:Abstract Background Long‐term maintenance of synaptic adaptations, assessed by long‐term potentiation (LTP), relies on gene induction, and can be impaired by pathological forms of tau protein in Alzheimer’s disease and related dementias (ADRD). We have previously shown that alterations in activity‐dependent gene expression profiles present in tauopathy mice are normalized by LM11A‐31 (C31), a small molecule p75 neurotrophin receptor (NTR) signaling modulator. However, altered gene expression levels represent only part of the complexity of the activity‐regulated transcriptional program. Since neuronal stimulation regulates alternative splicing of a number of activity‐regulated transcripts, and its disruption is associated with dysfunctional changes in ADRD, we aim to identify potential alternative splicing events related to tau‐mediated synaptic dysfunction and whether such alterations are influenced by treatment with a p75 NTR modulator. Method PS19 (P301S) and wildtype mice were treated with vehicle (Veh) or C31 by oral gavage at 6 months of age for 3 consecutive months. Gene translation‐ and protein synthesis‐dependent synaptic plasticity was induced by applying three events of theta burst stimulation (TBS). RNA sequencing on stimulated [(+) TBS] slices was used to generate activity‐related profiles of alternative splicing events at the isoform level. Result We identified axon guidance, glutamatergic synapse, long‐term potentiation and calcium signaling KEGG pathways among the top significant pathways with isoforms down‐regulated in (+) TBS PS19 relative to (+) WT slices. This isoform downregulation was substantially mitigated in (+) TBS slices from PS19 mice treated with C31 (see figure). For example, CACNA1H‐202, a splice‐variant that encodes a voltage‐gated calcium channel protein required for proper synaptic function, is found among the splice variants down‐regulated in Veh and up‐regulated in C31‐treated (+) TBS PS19 slices. Conversely, Prickle2‐204 isoform, associated with the formation of glutamatergic synapses, is up‐regulated in Veh and down‐regulated in C31‐treated (+) TBS PS19 slices. Currently, we are validating and examining the roles of these key C31‐modulated isoforms in neuronal function and synaptic strength as candidate molecular mechanisms involved in activity‐related effects contributing to tau‐induced neurodegeneration. Conclusion We identified neuronal activity‐related mRNA isoform modulation by C31, indicating that p75NTR signaling might influence alternative splicing events that compromise synapse function in ADRD.

Small molecule modulation of the p75 neurotrophin receptor inhibits multiple amyloid beta-induced tau pathologies

p75 neurotrophin receptor modulation in mild to moderate Alzheimer disease: a randomized, placebo-controlled phase 2a trial

Small molecule modulation of TrkB and TrkC neurotrophin receptors prevents cholinergic neuron atrophy in an Alzheimer's disease mouse model at an advanced pathological stage

Neuronal stimulation‐regulated RNA splicing defects in tauopathies are corrected by treatment with a p75 NTR modulator

Stabilizing the Retromer Complex in a Human Stem Cell Model of Alzheimer’s Disease Reduces TAU Phosphorylation Independently of Amyloid Precursor Protein

A TrkB and TrkC partial agonist restores deficits in synaptic function and promotes activity‐dependent synaptic and microglial transcriptomic changes in a late‐stage Alzheimer's mouse model

P3‐309: Overexpression of Hyperphosphorylated Tau Antagonizes Aβ‐potentiated Apoptosis with Preservation of Mitochondrial Elements

P2-296: Enhanced Proteolysis of Aβ Peptide Reduces Tau Phosphorylation and Neurofibrillary Tangle Formation in APP/tau Transgenic Mice

Modulation of p75-dependent motor neuron death by a small non-peptidyl mimetic of the neurotrophin loop 1 domain

A small‐molecule microtubule‐stabilizing agent safely reduces Aβ plaque and tau pathology in transgenic mouse models of Alzheimer's disease

Glymphatic inhibition exacerbates tau propagation in an Alzheimer's disease model

Mechanism of action deconvolution of the small-molecule pathological tau aggregation inhibitor Anle138b

A small molecule p38α MAPK inhibitor, MW150, attenuates behavioral deficits and neuronal dysfunction in a mouse model of mixed amyloid and vascular pathologies

Neurotoxic Soluble Amyloid Oligomers Drive Alzheimer’s Pathogenesis and Represent a Clinically Validated Target for Slowing Disease Progression

Modulation of Amyloid and Tau Aggregation to Alleviate Cognitive Impairment in a Transgenic Mouse Model of Alzheimer's Disease

Reduction of advanced tau‐mediated memory deficits by the MAP kinase p38γ

Site-specific phosphorylation of tau inhibits amyloid-β toxicity in Alzheimer’s mice

5-HT4 receptor agonists treatment reduces tau pathology and behavioral deficit in the PS19 mouse model of tauopathy

Conformation-selective tau monoclonal antibodies inhibit tau pathology in primary neurons and a mouse model of Alzheimer’s disease

Reduction of advanced tau-mediated memory deficits by the MAP kinase p38γ

Tetramethylpyrazine Nitrone (TBN) Reduces Amyloid β Deposition in Alzheimer's Disease Models by Modulating APP Expression, BACE1 Activity, and Autophagy Pathways